NO20061839L - Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav - Google Patents

Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav

Info

Publication number
NO20061839L
NO20061839L NO20061839A NO20061839A NO20061839L NO 20061839 L NO20061839 L NO 20061839L NO 20061839 A NO20061839 A NO 20061839A NO 20061839 A NO20061839 A NO 20061839A NO 20061839 L NO20061839 L NO 20061839L
Authority
NO
Norway
Prior art keywords
compositions containing
preparation
benzimidazole derivatives
compounds
salts
Prior art date
Application number
NO20061839A
Other languages
English (en)
Inventor
Christopher Walpole
Hua Yang
Daniel Page
Zipping Liu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20061839L publication Critical patent/NO20061839L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med Formel (I) eller farmasøytisk akseptable salter derav der R1, R2, R3 og R4 er som angitt i beskrivelsen. Videre beskrives salter og farmasøytiske preparater inneholdende forbindelsene som fremstilt. Forbindelsene finner anvendelse i terapi, særlig ved håndtering av smerte.
NO20061839A 2003-09-26 2006-04-26 Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav NO20061839L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302573A SE0302573D0 (sv) 2003-09-26 2003-09-26 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
PCT/GB2004/004124 WO2005030732A1 (en) 2003-09-26 2004-09-24 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Publications (1)

Publication Number Publication Date
NO20061839L true NO20061839L (no) 2006-06-26

Family

ID=29246982

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061839A NO20061839L (no) 2003-09-26 2006-04-26 Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav

Country Status (33)

Country Link
US (1) US8633235B2 (no)
EP (1) EP1670769B1 (no)
JP (1) JP4896721B2 (no)
KR (1) KR101170184B1 (no)
CN (2) CN1886379A (no)
AR (1) AR045819A1 (no)
AT (1) ATE430135T1 (no)
AU (1) AU2004276062B2 (no)
BR (1) BRPI0414780B8 (no)
CA (1) CA2539738C (no)
CO (1) CO5680443A2 (no)
CY (1) CY1110332T1 (no)
DE (1) DE602004020907D1 (no)
DK (1) DK1670769T3 (no)
ES (1) ES2324669T3 (no)
HR (1) HRP20090388T1 (no)
IL (1) IL174215A0 (no)
IS (1) IS8422A (no)
MX (1) MXPA06003197A (no)
MY (1) MY140630A (no)
NO (1) NO20061839L (no)
NZ (1) NZ545736A (no)
PL (1) PL1670769T3 (no)
PT (1) PT1670769E (no)
RU (1) RU2346938C2 (no)
SA (1) SA04250310B1 (no)
SE (1) SE0302573D0 (no)
SI (1) SI1670769T1 (no)
TW (1) TW200521117A (no)
UA (1) UA86776C2 (no)
UY (1) UY28536A1 (no)
WO (1) WO2005030732A1 (no)
ZA (3) ZA200602446B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UA87327C2 (ru) * 2004-09-24 2009-07-10 Астразенека Аб Производные бензимидазола, композиция, которая их содержит, их получение и применение
WO2006033630A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
WO2006033631A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
MX2007003105A (es) 2004-09-24 2007-06-07 Aztrazeneca Ab Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
EP1809607B1 (en) 2004-11-02 2008-12-17 Pfizer, Inc. Sulfonyl benzimidazole derivatives
JP2009502912A (ja) * 2005-07-29 2009-01-29 アストラゼネカ・アクチエボラーグ ジェミナル（（ジフルオロシクロアルキル）メチル）アミンの製造方法
TW200745049A (en) * 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
JP5159630B2 (ja) * 2006-09-13 2013-03-06 協和発酵キリン株式会社 縮環複素環誘導体
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
RU2454234C1 (ru) * 2011-03-16 2012-06-27 Константин Михайлович Аверин Соли 1,3-диэтилбензимидазолия - иммуностимулирующие средства и фармацевтические композиции на их основе
JP2015529692A (ja) * 2012-06-13 2015-10-08 サイテク・テクノロジー・コーポレーシヨン 置換クロマン化合物を含む安定剤組成物および使用方法
BR112014032538A2 (pt) 2012-06-26 2017-06-27 Bayer Pharma AG n-[4-(quinolin-4-ilóxi)ciclo-hexil(metil)] (hetero)arilcarboxamidas como antagonistas do receptor de andrógeno, produção e uso das mesmas como produtos medicinais
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN112010789A (zh) * 2019-05-31 2020-12-01 中国科学院上海药物研究所 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
GB202019335D0 (en) * 2020-12-08 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions
US20250171451A1 (en) * 2022-03-04 2025-05-29 Samjin Pharmaceutical Co., Ltd. Novel heterocyclic compound and pharmaceutical composition comprising same

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (no) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
EP0882718B1 (en) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
NZ519326A (en) * 2000-01-14 2005-02-25 Schering Ag 1,2-diarylbenzimidazoles for treating diseases that are associated with a microglia activation
US7329679B2 (en) * 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1758884A2 (en) 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
EP1765332A2 (en) 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
US8026237B2 (en) 2004-07-30 2011-09-27 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
US20060052421A1 (en) 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
WO2006033631A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
WO2006033630A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
WO2006033628A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1797074A4 (en) 2004-09-24 2009-04-01 Astrazeneca Ab COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND APPLICATIONS THEREOF IIII
JP2008514594A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用ｉ
EP1797075A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Benzimidazole derivatives and their use as cannabinoid receptor ligands
WO2006033633A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparations thereof and uses thereof ii
MX2007003105A (es) * 2004-09-24 2007-06-07 Aztrazeneca Ab Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
EP1809607B1 (en) 2004-11-02 2008-12-17 Pfizer, Inc. Sulfonyl benzimidazole derivatives
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds

Also Published As

Publication number Publication date
EP1670769A1 (en) 2006-06-21
CA2539738C (en) 2011-11-22
WO2005030732A1 (en) 2005-04-07
RU2346938C2 (ru) 2009-02-20
UY28536A1 (es) 2005-04-29
NZ545736A (en) 2009-11-27
DK1670769T3 (da) 2009-08-10
SI1670769T1 (sl) 2009-10-31
HK1089436A1 (en) 2006-12-01
US20080207612A1 (en) 2008-08-28
BRPI0414780B1 (pt) 2018-10-23
ZA200602446B (en) 2007-09-26
BRPI0414780A (pt) 2006-11-21
CO5680443A2 (es) 2006-09-29
PT1670769E (pt) 2009-07-09
EP1670769B1 (en) 2009-04-29
AR045819A1 (es) 2005-11-16
SA04250310B1 (ar) 2009-01-19
BRPI0414780B8 (pt) 2021-05-25
ZA200702131B (en) 2008-08-27
UA86776C2 (ru) 2009-05-25
CN102010373A (zh) 2011-04-13
PL1670769T3 (pl) 2009-09-30
CA2539738A1 (en) 2005-04-07
TW200521117A (en) 2005-07-01
HRP20090388T1 (hr) 2009-08-31
IL174215A0 (en) 2006-08-01
RU2006113371A (ru) 2007-11-10
KR20070001052A (ko) 2007-01-03
CY1110332T1 (el) 2015-01-14
ES2324669T3 (es) 2009-08-12
KR101170184B1 (ko) 2012-07-31
CN1886379A (zh) 2006-12-27
AU2004276062A1 (en) 2005-04-07
US8633235B2 (en) 2014-01-21
ZA200702226B (en) 2009-01-28
MXPA06003197A (es) 2006-06-23
JP4896721B2 (ja) 2012-03-14
DE602004020907D1 (de) 2009-06-10
SE0302573D0 (sv) 2003-09-26
MY140630A (en) 2010-01-15
AU2004276062B2 (en) 2008-05-22
ATE430135T1 (de) 2009-05-15
JP2007506721A (ja) 2007-03-22
IS8422A (is) 2006-04-21

Similar Documents

Publication Publication Date Title
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20065904L (no) Terapeutiske forbindelser
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20050828L (no) lndol-3-svovelderivater
NO20035210D0 (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
NO20074703L (no) Antibakterielle piperidinderivater
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
NO20092033L (no) Nye forbindelser
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0402762D0 (sv) Indazole sulphonamide derivatives
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
NO20064010L (no) Indazolderivater og farmasoytiske preparater inneholdelse slike
NO20052182L (no) Nye forbindelser
NO20062491L (no) Benzoksazinderivter og deres anvendelse
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application